At a glance
- Originator
- Developer Kyoto University; Nippon Chemiphar
- Class Anti-inflammatories; Antiasthmatics; Coumarins; Eye disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists; Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Liver disorders; Ocular inflammation